NV-SPHERICAM
18.4.2016 02:01:51 CEST | Business Wire | Press release
Sphericam 2, the world’s first 360˚ VR camera capable of self-stitching and livestreaming 4K video in real-time will start shipping this summer. Full-scale production is scheduled to begin at a U.S. production facility this July following a successful Kickstarter campaign and new $5 million investment from China’s Kingnet Technologies.
“The Sphericam 2 is like no other camera on the market. With a global shutter capable of shooting at 60 frames per second and the ability to self-stitch and livestream 4K video, it sets a new bar for performance. It’s also incredibly compact, roughly the size of a baseball. We designed the camera with professionals in mind which is why we’re thrilled use our presence at NAB to announce it will be available this summer” says Jeffrey Martin, Sphericam founder and CEO. The National Association of Broadcasters trade show in Las Vegas marks the first time the public will be able to view a live demo of the Sphericam 2.
The camera was first announced on Kickstarter in 2015 where it received backing of $450,000, more than four times the initial target.
“Our Kickstarter backers and pre-order customers will be the first to receive the Sphericam 2 once it ships. We also have large media and technology companies eager to start using the camera. The recent investment from Kingnet helps us not only accelerate our production timetable but to broaden our product and service portfolio,” says Martin.
The Shanghai-based online and mobile gaming company Kingnet is investing $5 million as part of a new strategic focus on VR content.
“We invested in Sphericam because it’s clear that it’s more than just a VR hardware company,” Wang Yue, CEO of Kingnet Technologies. “Sphericam is building a bridge between people’s real-world experiences and the VR space. The Sphericam 2 allows people to capture and share 360˚ video in a format that’s perfect for today’s virtual reality headsets and this is only the beginning.
Sphericam will be important part of Kingnet’s “platform+content+VR” strategy far into the future.”
The Sphericam 2 is available for pre-order at a cost of $2500.
Visit us at NAB 2016, Las Vegas, USA
April 16th – 21st
Booth N8022
North Hall, VR Pavilion
About Sphericam
Founded by American photographer Jeffrey Martin along with Dutch hardware specialist Servaes Joordens and software specialist Poppo Wit in 2014, Sphericam is dedicated to building groundbreaking 360˚ cameras to create original content for virtual reality platforms and interactive online media. The company’s newest product, called Sphericam 2, is an immersive capture device capable of self-stitching and streaming live 4K video at 60 frames per second. The company has offices in Prague, Haarlem, Haaren and Ljubljana.
Images and example 360˚ video content: http://bit.do/sphericam
View source version on businesswire.com: http://www.businesswire.com/news/home/20160417005021/en/
Contact:
Media contact
US:
Gaja Zornada
gaja@sphericam.com
+38-64-1215-430
+1-401-3-430-430
or
George
Krieger
press@sphericam.com
+1-831-717-7214
or
Europe:
Marc
Rettig
marc.Rettig@nelsonbostockunlimited.com
T
+44-7814-794253
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom